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Targeted delivery of an ADP-
ribosylating bacterial toxin into 
cancer cells
N.-I. Zahaf 1,*, A. E. Lang1,*, L. Kaiser1, C. D. Fichter2,3, S. Lassmann2,3,4,5,6, A. McCluskey7, 
A. Augspach1, K. Aktories1,3,5 & G. Schmidt1,3
The actin cytoskeleton is an attractive target for bacterial toxins. The ADP-ribosyltransferase TccC3 
from the insect bacterial pathogen Photorhabdus luminescence modifies actin to force its aggregation. 
We intended to transport the catalytic part of this toxin preferentially into cancer cells using a toxin 
transporter (Protective antigen, PA) which was redirected to Epidermal Growth Factor Receptors (EGFR) 
or to human EGF receptors 2 (HER2), which are overexpressed in several cancer cells. Protective antigen 
of anthrax toxin forms a pore through which the two catalytic parts (lethal factor and edema factor) or 
other proteins can be transported into mammalian cells. Here, we used PA as a double mutant (N682A, 
D683A; mPA) which cannot bind to the two natural anthrax receptors. Each mutated monomer is fused 
either to EGF or to an affibody directed against the human EGF receptor 2 (HER2). We established 
a cellular model system composed of two cell lines representing HER2 overexpressing esophageal 
adenocarcinomas (EACs) and EGFR overexpressing esophageal squamous cell carcinomas (ESCCs). We 
studied the specificity and efficiency of the re-directed anthrax pore for transport of TccC3 toxin and 
established Photorhabdus luminescence TccC3 as a toxin suitable for the development of a targeted 
toxin selectively killing cancer cells.
Pharmacological treatment of tumor cells is mainly based on causing damage of dividing cancerous and 
non-cancerous cells. This is accompanied by severe side effects. Therefore, more specific drugs have been 
developed. Among them are kinase inhibitors and antibodies. Unfortunately, no surface molecules exclusively 
expressed on tumor cells have been uncovered, which could be used to selectively attack transformed cells. 
However, much effort has been spent on the generation of specific antibodies against overexpressed surface pro-
teins. Approaches have included development of immunotoxins composed of an antibody directed against the 
overexpressed cell surface receptor and a catalytic domain of a toxin fused to it1–3. For higher selectivity of this 
artificial fusion-protein the toxin is devoid of its natural binding component4. Following the interaction of the 
chimeric protein with surface protein, the immunotoxin is endocytosed and has to be released from the endo-
some into the cytosol. This is an endogenous property of some toxins, which are able to cross the endosomal 
membrane. For this purpose acidification of the endosome and proteolytic cleavage of the toxins catalytic part is 
necessary5–7. Besides antibodies, growth factors have also been used as receptor binding component of bacterial 
toxins (named targeted toxins), because growth factor receptors are frequently overexpressed on tumor cells. Well 
established immunotoxins and targeted toxins contain the ADP-ribosyltransferases Pseudomonas exotoxin (PE) 
or diphtheria toxin (DT)3,8,9. Both modify elongation factor (EF) 2, leading to the inhibition of protein synthesis, 
cell cycle arrest and cell death10. Truncated diphtheria toxin covalently attached to interkeukin-2 (Denileukin 
diftitox, ONTAK) is approved for the treatment of cutaneous T-cell lymphomas (CTCL). It binds selectively to the 
interleukin-2 receptor (CD25+ ) on lymphocytes and is taken up by endocytosis11. Moreover, ONTAK is effective 
in the maintenance therapy for peripheral T-cell lymphomas with low appearance of adverse effects12. Therefore, 
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other well characterized bacterial toxins encompassing high catalytic activity and specificity against target mole-
cules should be tested as possible therapeutic strategies against cancer.
Some bacterial toxins are composed of two separate proteins: a pore-forming transport unit and a catalytic 
part delivered through the pore into the cytosol of mammalian cells13–16. Anthrax toxin consists of protective 
antigen (PA) and two enzymes: lethal factor (LF) and edema factor (EF)17. Following proteolytic activation, PA 
assembles to a heptameric pore initiated by receptor binding, endocytosis and acidification18,19. It inserts into the 
endosomal membrane to transport the effectors LF and EF into mammalian cells20. In artificial systems such a 
pore can be used to transport a variety of bacterial toxins into mammalian cells either following endocytosis or 
directly through the plasma membrane by acidification of the extracellular milieu21,22.
In our study, we used PA as a double mutant (N682A, D683A) which cannot bind to the two natural anthrax 
receptors, tumor endothelium marker-8 (TEM8) and capillary morphogenesis protein 2 (CMG2)15,23. For selec-
tive binding to tumor cells each mutated monomer (mPA) is fused either to EGF or to an affibody directed against 
the human EGF receptor 2 (HER2). Both fusion toxins have been shown to bind their cellular receptors and to 
mediate entry of different proteins into cells24.
Several protein toxins can be transported through the re-directed anthrax heptamer by fusing them to the 
N-terminal PA-binding domain of the natural effector LF (LFN). The truncated LFN has no catalytic activity. 
Here, we used the ADP-ribosyltransferase TccC3 (aa 679–960, hypervariable region - C3hvr) of the insect path-
ogen Photorhabdus luminescence as fusion partner. This toxin modifies actin at threonine-148, inhibits its inter-
action with actin-binding proteins like thymosin-β 4 and forces actin aggregation25,26. Therefore, actin-dependent 
processes cannot be executed anymore. The objective of these studies was to evaluate a cellular model system 
for testing specificity and efficiency of several bacterial toxins to be transported by the re-directed anthrax pore. 
Moreover, we intended to study suitability of the Photorhabdus luminescence toxin TccC3 catalytic part to be 
transported by mPA for killing cancer cells. We chose two cell lines of the two main histotypes of esophageal 
cancer, esophageal adenocarcinomas (EACs) and esophageal squamous cell carcinomas (ESCCs), which are char-
acterized by divergent overexpression of the two targeted receptors, EGF-receptor (EGFR) and HER2. OE21 cells 
as a member of the ESCC cell lines show high expression of EGFR forming mainly EGFR homodimers and only 
some EGFR/HER2 heterodimers, whereas OE33 cells as representative of EACs exhibit strong HER2 expression 
with the formation of HER2 homodimers and a lower amount of EGFR/HER2 heterodimers27.
Results
We have shown previously that the Photorhabdus luminescence toxin TccC3 catalyzes the ADP-ribosylation of 
actin at threonine-148. This modification blocks the interaction of actin with thymosin-β 4, an actin sequestering 
protein resulting in uncontrolled actin polymerization and subsequent cell death.
Generation of a TccC3 fusion protein which can be transported through the PA pore. For trans-
port through the re-directed PA-pore we generated a fusion toxin composed of the N-terminal 263 amino acids of 
anthrax lethal factor (LFN) and the hypervariable region of TccC3 (aa 679–960, C3hvr)28,29. LFN has no catalytic 
activity. It binds the PA heptamer and allows the transport of proteins through the PA pore. C3hvr is the minimal 
catalytically active domain of the Photorhabdus toxin TccC3 30. First, we tested whether the recombinant fusion 
toxin (named LFN-C3) was catalytically active. Therefore, HeLa cell lysates were incubated with LFN-C3, the 
full Photorhabdus TccC3 toxin as a positive control and without the toxin as negative control in the presence of 
32P-radio-labeled NAD+. The active catalytic domain of TccC3 catalyzes ADP-ribosylation of actin and therefore, 
actin is radio-labeled. This can be visualized following separation of the proteins by SDS-PAGE and exposure of 
the dried gel to a phosphor imager plate (Fig. 1). The data indicate that the fusion protein is folded correctly and 
is able to modify actin in cell lysates.
In a second experiment, the activity of the fusion toxin together with the anthrax PA (wildtype) was tested 
on cells. HeLa cells were treated with PA or LFN-C3 alone, with PA and LFN-C3 together or left untreated as 
Figure 1. Recombinant LFN-C3 is active: HeLa cell lysate was incubated with the purified recombinant 
fusion protein LFN-C3 in the presence of radio-labeled NAD+. As negative control lysate was incubated with 
radio-labeled NAD+ without LFN-C3, as positive control with NAD+ plus Photorhabdus complete TccC3 ADP-
ribosyltransferase (BC3). Shown is the readout of the dried SDS-PAGE as a typical result of three independent 
experiments.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:41252 | DOI: 10.1038/srep41252
indicated in the figure. Following 2 h of incubation photographs of the cells were taken. As shown in Fig. 2, 
only cells treated with PA together with the fusion toxin rounded up, showing that the fusion toxin is trans-
ported through the PA pore and is active in the cells. In contrast, the pore-forming PA alone nor LFN-C3 alone 
does change cellular morphology. To further exclude purification artifacts, we generated catalytically inactive 
LFN-C3(E943A) and a PA-mutant which can form oligomers on the cell surface without generating a functional 
pore (PA(F427A), Φ -clamp31). We combined each mutated protein with the respective wildtype counterpart 
for intoxication experiments with OE21 cells. As expected, only PA wildtype combined with LFN-C3 wildtype 
induced cell rounding (Fig. S1).
Specificity of the re-directed toxin transporter. The intoxication with PA-transported fusion toxins is 
not specific for cancer cells. It depends on the presence of one of the anthrax receptors, which are widely distrib-
uted in cells. To enhance specificity towards cancer cells, we used a PA double mutant (mPA) devoid of binding 
to the natural receptors. MPA was fused to either EGF or to ZHER2, an affibody directed against HER224. As 
a cellular model system, we used two well characterized esophageal carcinoma cell lines OE21 and OE33. In a 
previous study, it was shown that the squamous carcinoma cell line OE21 expresses high amounts of EGF recep-
tors on their surface but very little HER2. The adenocarcinoma cell line OE33 on the other hand over-expresses 
HER2 and a small amount of EGFR (Fig. 3a,b 27). Encompassing these properties, the two cell lines are a useful 
model system to study the specificity of the re-directed toxin transporters. We intended to analyze the specific 
uptake of LFN-C3 via the re-directed toxin transporters into either cell line, OE21 or OE33 cells. Therefore, cells 
were incubated with PA, mPA-EGF or mPA-ZHER2, respectively together with LFN-C3 or left untreated for 4 or 
24 (Fig. S1) hours as indicated. As shown in Fig. 4a, OE21 cells treated with mPA-ZHER2 plus LFN-C3 did not 
round up within 4 and 24 h (Fig. S2), whereas only cells treated with mPA-EGF plus LFN-C3 or PA plus LFN-C3 
rounded up within 4 h. In contrast, OE33 cells treated with analogous protein combinations rounded up when 
incubated with PA plus LFN-C3, mPA-ZHER2 plus LFN-C3 and with mPA-EGF plus LFN-C3 (Fig. 4b). The data 
show that mPA-ZHER2 mediates entry of LFN-C3 into HER2-positive OE33 cells whereas OE21 cells show no 
morphological response. Also actin staining of the cells following treatment with the above described protein 
combinations showed the specificity of mPA-ZHER2 for OE33 cells (Fig. S3). Only in OE21 cells treated with PA 
plus LFN-C3 or mPA-EGF plus LFN-C3 the actin cytoskeleton clustered, indicating that the fusion-toxin entered 
the cells. Actin clustering can be visualized better at earlier time points of intoxication, shown in Fig. 5. The pore 
forming unit mPA-ZHER2 cannot bind sufficiently to OE21 cells and therefore is not able to mediate entry of 
LFN-C3.
Quantitative evaluation of the specificity. To evaluate the specificity of mPA-ZHER2 in a quantita-
tive manner, we performed a dose response analysis using post-ADP-ribosylation, apoptosis (caspase activity) 
and cell viability assays. For post-ADP-ribosylation, OE21 and OE33 cells were treated with the proteins indi-
cated. Cells were lysed and the lysates were incubated with LFN-C3 in the presence of radioactive NAD+. In this 
Figure 2. Cell rounding induced by LFN-C3: HeLa cells were treated with PA (10 nM), LFN-C3 (8 nM), 
a combination of both or left untreated as indicated at 37 °C. Photographs were taken 2 h following 
intoxication. Shown is a typical result of 3 independent experiments.
www.nature.com/scientificreports/
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experiment only actin, which was not modified in the living cells by the previous treatment, is labeled. Strong 
labeling in the lysates thus indicates less modification of actin within the cell. The results shown in Fig. 6 are in 
line with the morphological studies: In OE21 cells only mPA-EGF guided LFN-C3 into the cytosol, whereas in 
OE33 both mPA-EGF and mPA-ZHER2 allowed entry of the fusion-toxin into cells. However, mPA-ZHER2 
seemed to be more effective. There was no effect of the transporters alone on the cell lines (Fig. 6b). To get more 
insight into the quantitative differences of the binding/transport capacity of the PA proteins, dose response anal-
ysis using different concentrations of the transporters and a fixed concentration of LFN-C3 for intoxication of 
the two OE cell lines was performed. Figure 6c shows that in OE21 cells the amount of actin ADP-ribosylated 
through action of the targeted toxin increased with increasing concentrations of mPA-EGF and LFN-C3, whereas 
there was no ADP-ribosylation detectable in lysates of OE21 cells treated with the highest concentration of 
mPA-ZHER2 and LFN-C3. Representative Western blots are shown in Fig. S4. In OE33 cells both transporters 
led to concentration-dependent ADP-ribosylation of actin. However, mPA-ZHER2 was more effective. The calcu-
lated effective concentration to get 50% of the maximal effect (EC50) of these experiments are depicted in Table 1.
Figure 3. OE21 cells express high amounts of EGF receptors and little HER2, whereas OE33 cells express 
HER2 and a small amount of EGFR. (a) Western blot as a typical result of more than three independent 
experiments (b) immunofluorescence with specific antibodies against EGFR and HER2 as indicated, shown are 
typical stainings of more than 50 cells monitored.
Figure 4. Cell specific cell rounding induced by LFN-C3 mediated by different PA transporters: OE21 (a) and 
OE33 (b) cells were incubated with the following proteins as indicated: PA (10 nM), mPA-EGF (10 nM), mPA-
ZHER2 (10 nM), LFN-C3 (8 nM). Photos were taken after 4 h of incubation. A typical result of 3 independent 
experiments is shown.
www.nature.com/scientificreports/
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Effect on cancer cell survival/cell death. A second approach to study toxin-mediated effects was the 
detection of tumor cell death. First, we studied caspase activity induced by actin clustering using an Apo1 assay 
(see materials and methods). OE33 cells responded to toxin treatment with caspase activation and apoptosis 
in a concentration dependent manner (Fig. 7). In contrast, the highest concentration of the PA protein with-
out addition of LFN-C3 did not induce caspase activation (Fig. S5). In line with the post-ADP-ribosylation, the 
mPA-ZHER2 transporter was more effective (Fig. 7, EC50 shown in Table 1). Surprisingly, OE21 cells did not show 
detectable caspase activity following intoxication with mPA-EGF or mPA-ZHER2 (Fig. 7). However, poly (ADP 
Ribose) polymerase (PARP) -cleavage was induced in OE21 cells treated with PA and LFN-C3 and in cells treated 
with mPA-EGF and LFN-C3 (Fig. S6). Morphological changes, actin clustering and post-ADP-ribosylation 
proved uptake and action of the catalytic LFN-C3.
Several forms of cell death are known (e.g. apoptosis, pyroptosis, methuosis) some of which are characterized 
by missing caspase activity. Therefore, we additionally studied cell viability following intoxication with increasing 
concentrations of PA proteins and a constant concentration of LFN-C3. In line with the post-ADP-ribosylation, 
the mPA-ZHER2 transporter together with LFN-C3 did not lead to cell death of OE21 cells. The single compo-
nents did not significantly change viability of the cells (Fig. S7). Moreover, mPA-EGF combined with LFN-C3 
decreased cell-viability of OE21 cells in a concentration-dependent manner (Fig. 8, calculated EC50 shown in 
Table 1). In line with the previous experiments, mPA-ZHER2 leads to slightly more efficient transport of LFN-C3 
into OE33 cells compared to mPA-EGF (EC50 in Table 1), which was not as obvious in this experiment as com-
pared to former ones.
Comparison of the EC50 values of all experiments showed an over 100-fold increase in efficacy of 
mPA-ZHER2-mediated toxin transport into OE33 cells, which express a higher amount of HER2 compared to 
OE21 cells (Table 1). In the concentration range tested, there was no measurable toxic effect of mPA-ZHER2 
combined with LFN-C3 in OE21 cells, which do weakly express HER2. The data show that OE21 and OE33 cells 
are a useful test system to evaluate selectivity of redirected toxin transporters. Moreover, LFN-C3 is a useful toxic 
component with the ability to kill cancer cells with little or no influence on cells which do not express or only 
weakly present the respective surface receptor of the carrier.
Discussion
In recent years, much effort has been spent on the identification of surface molecules, exclusively expressed on 
tumor cells. Although no specific tumor marker has been uncovered so far, some proteins are found enriched on 
specific cancer cell type surfaces allowing more efficient uptake of cytostatic drugs and immunotoxins. Using two 
well characterized esophageal cancer cell lines, OE21 as a typical esophageal squamous cell carcinoma (ESCC) 
showing high expression of EGFR and OE33 esophageal adenocarcinoma (EAC), characterized by high expres-
sion of HER2, we established a model system to study the specificity of engineered toxins directed to surface 
molecules, which are highly expressed on several tumor cells. For example, HER2 is overexpressed in about 20% 
of breast cancers (Nitta, 2016).
Most bacterial toxins are composed of several, independent domains, which encompass diverse functions. 
Targeting a bacterial toxin to a specific surface molecule can thus be achieved by exchanging the receptor binding 
domain of the toxin with a receptor binding domain of another protein having high affinity towards the chosen 
receptor32. Following endocytosis of the chimeric toxin the toxin’s catalytic domain has to be released from the 
endosome into the cytosol. This translocation step is not well understood. It requires hydrophobic amino acid 
Figure 5. Uncontrolled actin clustering in OE cells induced by LFN-C3 mediated by different PA 
transporters: OE21 cells and OE33 cells were treated with mPA-EGF (10 nM), mPA-ZHER2 (10 nM), LFN-
C3 (8 nM) as indicated. After 90 min cells were fixed and stained with Rhodamine phalloidin. The experiment 
was performed three times with similar results.
www.nature.com/scientificreports/
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Figure 6. Post-ADP-ribosylation of cell-lysates (a,b): OE21 cells and OE33 cells were treated with PA (10 nM), 
mPA-EGF (10 nM), mPA-ZHER2 (10 nM), LFN-C3 (8 nM) for 4 h, as indicated, washed and lysed. Lysates were 
than incubated with LFN-C3 in the presence of radio-labeled NAD+. Proteins of the lysates were separated 
by SDS-PAGE. Following drying of the gels labeled protein bands were detected by phosphorimaging and 
quantified. Labeled actin of an untreated control was set as 100%. Data give the median of three experiments 
plus standard deviation. Significance was analyzed using GraphPad Prism 5 (***p < 0,001, **p < 0,01, 
*p < 0,05). Post-ADP-ribosylation of cell-lysates following intoxication as dose response analysis (c): OE21 or 
OE33 cells were treated with increasing concentrations of mPA-EGF (gray, 0.01 nM to 10 nM) or mPA-ZHER2 
(black, 0.01 nM to 10 nM) and a fixed concentration of LFN-C3 (8 nM) for 4 h, as indicated. Lysates were 
prepared and treated as in (a). For each experiment a representative Western blot is shown in Fig. S4.
EC50 Values
OE21 OE33
Assay mPA-ZHER2 mPA-EGF mPA-ZHER2 mPA-EGF
ADP-ribosylation > 10 0.5 0.1 6
Caspase 3/7 activation > 10 > 10 2.5 5.2
Cell viability > 100 5 2 7
Table 1. EC50 values of targeted toxins.
Figure 7. Caspase activity of toxin-treated cells: OE21 or OE33 cells were treated with increasing 
concentrations of mPA-EGF (gray, 0.1 nM to 100 nM) or mPA-ZHER2 (black, 0.1 nM to 100 nM) and a 
fixed concentration of LFN-C3 (8 nM) for 24 h, as indicated. Lysates were prepared and tested for caspase 3/7 
activity. Staurosporine was used as positive control.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:41252 | DOI: 10.1038/srep41252
stretches used for insertion into the endosomal membrane. This hydrophobic domain may limit the successful 
expression of the recombinant protein and therefore the functionality of several engineered toxins.
Instead of generating a fusion toxin, we used a targeted toxin transporter based on the anthrax toxin33. Seven 
monomers of this transporter bind to the cell surface and form a pore in the endosomal membrane. Binding of 
the monomers to the natural anthrax receptors is prohibited by two mutations. Instead, the mutated monomers 
are re-directed to EGFR or HER2, receptors overexpressed on the surface of cancer cells, by fusion of EGF or of 
an affibody directed against HER2 to the N-terminus of mPA, respectively24. The first advantage of this dimeric 
system is the higher avidity of the transporter towards the cancer cell, because each subunit of the heptameric 
pore is fused to EGF or ZHER2 and therefore has seven possible binding sites on the cell surface. The second 
advantage is that no translocation domain of the catalytic part is necessary for its transport into the cytosol, which 
often hampers recombinant expression. Using an established targeted transporter system many different enzymes 
can potentially be studied. Here, we used the Photorhabdus luminescent ADP-ribosyltransferase C3. This toxin 
modifies actin at a unique site (threonine-148) resulting in actin aggregation by inhibiting binding of the actin 
sequestering protein thymosin-β 4 and leading to cell death34.
The two cell lines of the two main histotypes of esophageal cancer expressing divergent amounts of the 
two targeted receptors, EGF-receptor (EGFR) and HER2 emerge as an ideal model system to compare surface 
receptor-dependent toxin uptake and efficiency. Although both cell lines express EGFR and HER2, the stronger 
HER2 expression of OE33 mediate an about 100-fold higher specificity towards mPA-ZHER2 mediated intox-
ication. OE21 cells marginally express HER2, however, there is only low (if at all) intoxication of the cells with 
mPA-ZHER2 used as toxin transporter. This indicates that a crucial number of surface molecules must be accessi-
ble for successful binding and/or uptake of the toxin ensuring low unspecific toxicity. In former studies, Mechaly 
et al. used mPA-EGF for delivery of a fusion of LFN and the catalytic domain of diphtheria toxin into human 
epidermoid carcinoma cells (A431) which have a very strong expression of EGFR. Specificity over EGFR negative 
Chinese Hamster Ovary (CHO) cells was at least 1:1000 24. Here, we used two mammalian cell-lines (OE21 and 
OE33) expressing the EGF and HER2 receptors in different amounts and still reached a selectivity of about 1:100, 
respectively. Besides the total amount of surface standing receptors, other cellular properties like membrane fluid-
ity (for insertion of the toxin pore) and chaperone content (for refolding the transported catalytic toxin part) may 
be crucial for the activity of the targeted toxin. Our model system excludes such differences largely, because of the 
two cell lines acting crossover as positive and negative control, respectively. Compared to other studies using PA 
as a protein transport system (for excellent review see ref. 35), we used a different catalytic toxin, which targets 
the cytoskeleton instead of blocking protein synthesis. The Photorhabdus luminescence toxin TccC3 catalyzes the 
ADP-ribosylation of actin thereby forcing uncontrolled actin polymerization and subsequent cell death29. The 
modification occurs with monomeric and polymerized actin and should be completely independent from the cell 
cycle and state of cells, which still has to be shown26. Moreover, blocking the functionality of the actin cytoskel-
eton should inhibit migration of tumor cells, which is a prerequisite for metastasis. In OE33 cells toxin-induced 
actin aggregation induces apoptosis. In OE21 cells TccC3 also induces cell death and PARP-cleavage. Therefore, 
the two cell lines used in this study build a useful model system to analyze several toxins as potential protein car-
goes delivered by the targeted toxin transporters mPA-EGF and mPA-ZHER2.
Methods
Construction of the LFN-fusion toxins. The N-terminal 263 amino residues of LF (LFN) were amplified 
and cloned into the pET-28a (+ ) vector (Novagen, EMD Biosciences). PCR was performed with following primers: 
sense primer 5′ -cat atg gcg ggc ggt cat ggt ga-3′ and antisense primer 5′ -gga tcc ccg ttg atc ttt aag ttc ttc caa gg-3′ . 
For amplification of the ADP-ribosyltransferase domain hvr of TccC3 (residues 679–960), PCR was performed with 
sense primer 5′ -gga tcc atg cca aca att gca gaa cgc ata gca-3′ and antisense primer 5′ -ctc gag tta tct ctt atg agg ttt tac att 
ttt aag c-3′ . The PCR product of TccC3hvr with flanking BamHI and XhoI restriction sites was cloned into the LFN-
pET-28a (+ ) vector. Each construct was verified by sequencing. For construction of the catalytically inactive mutant, 
LFN-C3(E943A) was generated by quick-change PCR, using the following primers: sense 5′ gga ccg gta aat gat gca 
Figure 8. Cell viability of esophageal cancer cells: OE21 or OE33 cells were treated with increasing 
concentrations of mPA-EGF (gray, 0.1 nM to 100 nM) or mPA-ZHER2 (black, 0.1 nM to 100 nM) and a 
fixed concentration of LFN-C3 (8 nM), as indicated. Cell viability of the OE21 cells was tested after 24 h with 
the CellTiter-Blue kit (Promega). Cell viability of the OE33 cells was tested after 48 h with the CellTiter-Glo kit 
(Promega).
www.nature.com/scientificreports/
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gca att tca ttt ctg aca ac 3′ and antisense primer 5′ -gtt gtc aga aat gaa att gct gca tca ttt acc ggt cc-3′ . The construct was 
verified by sequencing. The PA Φ clamp mutant (PA(F427A)) was generated as described in ref. 31.
Cell culture/Intoxication. OE21 and OE33 cells were grown in RPMI 1640 medium supplemented with 
10% fetal calf serum, L-Glutamine (2 mM), streptomycin (4 mM) penicillin (4 mM) and 1% non-essential amino 
acids. HeLa cells were cultivated in Dulbecco’s Modified Eagle medium supplemented with 10% fetal calf serum, 
L-Glutamine (2 mM), streptomycin (4 mM) penicillin (4mM) and 1% non-essential amino acids. All cell lines 
were cultivated in humidified atmosphere of 5% CO2 at 37 °C and checked negative for mycoplasma monthly.
For intoxication, OE21 and OE33 cells were treated in culture medium (0.5% FCS) with the concentrations 
and times indicated and a confluency between 60 to 90%. Cells were then washed once with phosphate-buffered 
saline (PBS) and lysed with 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 2 mM MgCl2, 10% glycerol and 1% Nonidet 
P-40 for 10 min at 4 °C. Cells were harvested using a rubber policeman and centrifuged at 14000 RPM for 15 min 
at 4 °C.
Protein concentration was measured and adjusted using the bicinchoninic acid assay or the Roti® -quant fol-
lowing manufacturer’s instructions.
Actin staining. Cells were seeded on glass coverslips overnight, then intoxicated in culture medium 
(0.5% FCS) for 90 min or 4 h with according concentrations. After washing with PBS, cells were fixed in fix-
ation buffer (3.7% paraformaldehyde, 0.1% Triton in PBS) for 10 min at room temperature. Cover slips were 
washed three times with PBS and incubated for 1 h with Phalloidin-TRITC (Tetramethyl rhodamine B iso-
thiocyanate). Coverslips were washed 3 times then dried overnight with Moviol supplemented with DAPI 
(4′,6-diamidino-2-phenylindole) for nuclear staining. Staining was visualized by fluorescence microscopy.
In vitro ADP-ribosylation experiment. For ADP-ribosylation of actin and RhoA, cell lysates were incu-
bated in a reaction mix (25 nM TEA pH 7.5, 10 mM DTT, 15 mM MgCl2 and 12 mM thymidine) with 5 μ g/mL of 
toxins and 0.5 μ Ci of radioactive [32P] NAD. The reaction was incubated for 15 min at 37 °C. Proteins were sepa-
rated by SDS-PAGE (12.5%) and gels were dried for 1h followed by autoradiography. For loading control, RhoA 
was additionally modified by adding ADP-ribosylating toxin C3 (Clostridium botulinum) to the reaction mix.
Purification of proteins. BL21 (DE3) bacteria were transformed with 100 ng DNA. Protein expression was 
induced with 75 μ M isopropyl β -D-1-thiogalactopyranoside (IPTG) then cells were grown at 28 °C overnight in 
Luria-Bertani (LB) medium supplemented with antibiotics (Ampicillin or Kanamycin).
Bacteria were harvested by centrifugation at 6000 rpm for 15 min at 4 °C and lysed in lysis buffer (300 mM 
NaCl, 20 mM Tris-HCl, 500 μ M ethylenediaminetetraacetic acid (EDTA) pH 8.5) supplemented with 5 μ g/ml 
DNAse, 1 mg/ml Lysozym and 200 mM phenylmethanesulfonyl fluoride (PMSF). Cells were sonicated and 
the lysates centrifuged for 45 min at 14000 rpm at 4 °C. The supernatant was incubated with Protino-Ni-IDA 
(Macherey-Nagel) for 2 h at 4 °C and loaded on PD-10 columns. His-tagged proteins were eluted with an elution 
buffer (500 mM NaCl, 20 mM Tris-HCl, 0.05% Tween 20, 1 mM EDTA, 500 mM Imidazole pH 8.5). After elution, 
proteins were dialyzed overnight in 150 mM NaCl, 50 mM Tris-HCl, and 1 mM EDTA pH 8.5. Proteins were then 
centrifuged at 14000 rpm for 15 min and stored in glycerol (40%). Purity of the recombinant proteins was about 
80% (LFN-C3) and about 20% (mPA-EGF, mPA-ZHER2) of total protein.
Caspase 3/7 activation measurements, Cell viability measurements. Cells were seeded in a 96 
wells plate overnight. Cells were then intoxicated in culture medium (0.5% FCS) with indicated concentra-
tions for 24 h. Staurosporine was added for 17 h. Caspase 3/7 activation was measured using the Apo-ONE® 
Homogenous Caspase-3/7 Assay (Promega), following the manufacturer’s protocol. Cells were incubated with 
reagent for 1 h at room temperature. Cell viability of OE21 cells was measured using the CellTiter-Blue® Cell 
Viability kit (Promega), following the manufacturer’s protocol. Cells were incubated with reagent for 1 h at 37 °C. 
Because no cell death could be measured using the CellTiter-Blue® Cell Viability kit, viability of OE33 cells was 
measured using the CellTiter-Glo® Kit (Promega), with higher sensitivity, following the manufacturer’s protocol. 
Cells were incubated at RT for 10 min.
Indirect immunofluorescence. Cells were grown on coverslips, fixed in 2% PFA, washed in PBS and per-
meabilized in 0.5% (v/v) Tritron X-100 in PBS. After PBS washing, cells were incubated with blocking buffer (PBS 
containing 5.0% (v/v) normal goat serum and 0.3% (v/v) Tritron X-100). Diluted primary antibodies (mouse 
anti-human EGFR clone H11 (Dako) and polyclonal rabbit anti-human c-erbB-2 Oncoprotein (Dako)) were 
incubated overnight at 4 °C. Cells were rinsed with PBS and 1:200 diluted fluorescently labelled secondary anti-
bodies (goat-anti-mouse IgG-Alexa488 (Invitrogen) and goat-anti-rabbit IgG-Alexa568 (Invitrogen)), were incu-
bated for 1 hour at RT. After washing with PBS and distilled water, cell nuclei were counterstained with DAPI 
(Vector Laboratories). Stainings were evaluated at a fluorescence microscope (Axioplan2 imaging microscope 
equipped with a Plan-Neofluar 40x/1.3 oil objective, Carl Zeiss MicroImaging) with slider module. Image stacks 
at 0.9 μ m intervals were taken and converted into 3D view by AxioVision software (Carl Zeiss MicroImaging).
Western Blot. Preparation of total protein was perfomed using the Qproteome™ Mammalian Protein Prep 
Kit (Qiagen) according to the manufacturer’s protocols. Determination of protein concentration was performed 
using the DC Protein Assay (Bio-Rad) according to the manufacturer’s protocols. 15 μ g of total protein extracts 
per lane were loaded onto 8% polyacrylamide gels. Proteins were transferred onto Amersham™ Hybond™ ECL 
Nitrocellulose Membrane (GE Healthcare) by Semi-Dry blot. The membrane was blocked in 5% (m/v) nonfat 
dried milk powder in Tris buffered saline with Tween (TBST). Then the primary antibodies diluted in 5% (m/v) 
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nonfat dried milk powder in TBST (mouse anti-human EGFR clone H11 (Dako), mouse anti-β -Actin clone 
AC-15 (Sigma-Aldrich)) or 5% BSA in TBST (polyclonal rabbit anti-HER2/ErbB2 (Cell Signaling)) were incu-
bated. After HRP conjugated secondary antibody (Dianova) incubation, the membrane was incubated with ECL 
reagents (Thermo Scientific). Chemiluminescence detection and imaging was done with the Fusion Fx7 System 
and the FusionCapt Advance Software (Vilber Lourmat).
Statistics. Statistical significance of the data was analyzed by one-way-Anova, including all data measured 
and by performing a Bonferroni test for selected pairs of columns as indicated in the figures. All data were nor-
malized to the untreated control.
For the EC50 calculation: The experiments were plotted using Graphpad 5 and the concentrations were trans-
formed to a logarithm. The non-linear regression fit was chosen and the dose response stimulation was defined as 
log agonist vs normalized response (to the untreated control).
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